论文部分内容阅读
【目的】探讨培美曲塞联合顺铂(PC)方案同步放疗治疗晚期肺腺癌的临床效果。【方法】选取本院肿瘤科收治的98例晚期肺腺癌患者，随机分为研究组和对照组，每组各49例，研究组采用 PC 方案联合同步放疗治疗，对照组采用紫杉醇+顺铂结合同步放疗治疗，观察比较两组患者的近期疗效、血清癌胚抗原(CEA)、鳞状细胞抗原(SCCAg)、糖抗原(CA125)、神经元特异性烯醇化酶(NSE)的变化及并发症发生情况，远期预后。【结果】研究组患者的缓解率为37.50%(18/48)、总有效率为81.25%(39/48)，均显著高于对照组患者的25.53%(12/47)、65.96%(31/47)，但两组相比较差异无显著性(P >0.05)；治疗后研究组患者的血清 CEA、SCCAg、CA125、NSE水平显著低于对照组，且差异有显著性(P <0.05)；研究组的Ⅲ度、Ⅳ度骨髓抑制、消化道反应、皮疹、肝功能损害发生率显著低于对照组，且差异有显著性(P <0.05)；研究组患者的中位生存时间为13.5个月显著长于对照组的10.3个月(P 0.05).The serum CEA,SCCAg,CA125,and NSE levels be-tween the two groups had significant difference (P <0.05).After treatment,the serum CEA,SCCAg,CA125, and NSE levels were significantly lower in the observation group than in the control group (P <0.05).Appear-ance of third and fourth degree bone marrow suppression,gastrointestinal reactions,rashes,and liver dysfunction was significantly lower in the observation group than in the control group and the difference was statistically signif-icant (P <0.05).The observation group had a median survival time of 13.5 months,and was significantly longer than the 10.3 months in the control group (P <0.05)(log-rankχ2=7.074,P =0.016<0.05).[Conclusion]PC program with concurrent chemotherapy in advanced lung cancer is much safer and provides superior results to gemcitabine(change to taxol)combinated chemotherapy.